Obsidian Therapeutics, founded in 2015, aspires to extend adoptive immunotherapy to every patient with cancer. We do this by building cell therapies with pharmacologic operating systems to provide treating physicians with precise and dynamic control of engineered cells in patients.

Obsidian creates adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs. With this unique approach, we can dramatically improve the current generation of cell therapies.

Headquartered in Cambridge, Massachusetts, Obsidian has assembled an industry-leading team of experts in immunology, cell therapy, and oncology. We continue to build our team so please check our website (www.obsidiantx.com) often for job opportunities.